Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Treasury Shares (2020 - 2025)

Apellis Pharmaceuticals has reported Treasury Shares over the past 6 years, most recently at $547000.0 for Q4 2025.

  • Quarterly results put Treasury Shares at $547000.0 for Q4 2025, down 86.19% from a year ago — trailing twelve months through Dec 2025 was $547000.0 (down 86.19% YoY), and the annual figure for FY2025 was $547000.0, down 86.19%.
  • Treasury Shares for Q4 2025 was $547000.0 at Apellis Pharmaceuticals, down from $4.0 million in the prior quarter.
  • Over the last five years, Treasury Shares for APLS hit a ceiling of $4.3 million in Q4 2023 and a floor of $547000.0 in Q4 2025.
  • Median Treasury Shares over the past 5 years was $3.6 million (2022), compared with a mean of $2.7 million.
  • Biggest five-year swings in Treasury Shares: surged 191.59% in 2022 and later crashed 86.19% in 2025.
  • Apellis Pharmaceuticals' Treasury Shares stood at $1.2 million in 2021, then surged by 191.59% to $3.6 million in 2022, then increased by 20.41% to $4.3 million in 2023, then fell by 7.91% to $4.0 million in 2024, then tumbled by 86.19% to $547000.0 in 2025.
  • The last three reported values for Treasury Shares were $547000.0 (Q4 2025), $4.0 million (Q4 2024), and $4.3 million (Q4 2023) per Business Quant data.